

"Express Mail" Label No. EV 566969845 US  
Date of Deposit February 17

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: 

Aaron Hokamura

PATENT  
Attorney Docket No.: 68-003910US  
Client Reference No.: CNC-A0213P2-US

**Rec'd PCT/PTO 17 FEB 2006**

#8

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

NAKAMURA and KATAGIRI

Application No.: 10/530,217

Int'l Application No.: PCT/JP03/09589

Int'l Filing Date: July 29, 2003

For: GENES AND POLYPEPTIDES  
RELATING TO HUMAN MYELOID  
LEUKEMIA

Examiner:

Art Unit:

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed in compliance with the provisions of 37 CFR §1.98(a)(2). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

References AA, AB, AF, AG, AI, AJ, AL, AM and AS-AX were cited in an International Search Report in a corresponding application. A copy of the Search Report is enclosed.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ath  
60705919 v1

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/530,217	
			Filing Date	July 29, 2003	
			First Named Inventor	Nakamura, Yusuke	
			Art Unit		
			Examiner Name		
Sheet	1	of	3	Attorney Docket Number	082368-003910US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AA	WO	02/05843	A2/A3	01-24-2002	Exelixis, Inc.		<input type="checkbox"/>
	AB	WO	03/000928	A2/A3	01-03-2003	Odin Medical A/S		<input type="checkbox"/>
	AC	WO	2004/031409	A2/A3	04-15-2004	Oncotherapy Science, Inc.; and Japan as represented by the President of the University of Tokyo		<input type="checkbox"/>
	AD	WO	2004/031775	A2/A3	04-15-2004	Oncotherapy Science, Inc.; and Japan as represented by the President of the University of Tokyo		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60705919 v1

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/530,217
				Filing Date	July 29, 2003
				First Named Inventor	Nakamura, Yusuke
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	082368-003910US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AE	GALLIO, Marco and Per Kylsten; "Providencia may help find a function for a novel, widespread protein family"; <u>Current Biology</u> 10(19):R693-R694, 2000	<input type="checkbox"/>
	AF	KANETA, Yasuyuki <i>et al.</i> ; "Prediction of Sensitivity of ST1571 among Chronic Myeloid Leukemia Patients by Genome-wide cDNA Microarray Analysis"; <u>Jpn. J. Cancer. Res.</u> 93:849-856, August 2002	<input type="checkbox"/>
	AG	KIELMAN, Menno F. <i>et al.</i> ; "Characterization and Comparison of the Human and Mouse <i>Dist1/a-globin</i> Complex Reveals a Tightly Packed Multiple Gene Cluster Containing Differentially Expressed Transcription Units"; <u>Genomics</u> 32:341-351, 1996	<input type="checkbox"/>
	AH	KIKUCHI, Takefumi <i>et al.</i> ; "Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs"; <u>Oncogene</u> 22:2192-2205, 2003	<input type="checkbox"/>
	AI	KLÄMBT, Christian; "EGF Receptor Signaling: Roles of Star and Rhomboid Revealed"; <u>Current Biology</u> 12:R21-R23, January 8, 2002	<input type="checkbox"/>
	AJ	KOONIN, Eugene V. <i>et al.</i> ; "The rhomboids: a nearly ubiquitous family of intramembrane serine proteases that probably evolved by multiple ancient horizontal gene transfers"; <u>Genome Biology</u> 4(3):R19.1-R19.12, February 28, 2003	<input type="checkbox"/>
	AK	LEE, Jeffrey R. <i>et al.</i> ; "Regulated Intracellular Ligand Transport and Proteolysis Control EGF Signal Activation in <i>Drosophila</i> "; <u>Cell</u> 107:161-171, October 19, 2001	<input type="checkbox"/>
	AL	LI, Huiyu <i>et al.</i> ; "cDNA Microarray Analysis of Chronic Myeloid Leukemia"; <u>Int. J. Hematol.</u> 75:388-393, 2002	<input type="checkbox"/>
	AM	OHMINE, Ken <i>et al.</i> ; "Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells"; <u>Oncogene</u> 20:8249-8257, 2001	<input type="checkbox"/>
	AN	OKUTSU, Jun-ichi <i>et al.</i> ; "Prediction of chemosensitivity for Patients with Acute Myeloid Leukemia, According to Expression Levels of 28 Genes Selected by Genome-wide Complementary DNA Microarray Analysis"; <u>Molecular Cancer Therapeutics</u> 1:1035-1042, October 2002	<input type="checkbox"/>
	AO	RATHER, Philip N. and Elizabeth Orosz; "Characterization of <i>aarA</i> , a Pleiotropic Negative Regulator of the 2'-N-Acetyltransferase in <i>Providencia stuartii</i> "; <u>Journal of Bacteriology</u> 176(16):5140-5144, August 1994	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/530,217
				Filing Date	July 29, 2003
				First Named Inventor	Nakamura, Yusuke
				Art Unit	
Examiner Name					
Attorney Docket Number	082368-003910US				
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	AP	URBAN, Sinisa <i>et al.</i> ; "Drosophila Rhomboid-1 Defines a Family of Putative Intramembrane Serine Proteases"; <u>Cell</u> 107:173-182, October 19, 2001		
	AQ	URBAN, Sinisa <i>et al.</i> ; "Conservation of Intramembrane Proteolytic Activity and Substrate Specificity in Prokaryotic and Eukaryotic Rhomboids"; <u>Current Biology</u> 12:1507-1512, September 3, 2002		
	AR	URBAN, Sinisa <i>et al.</i> ; "A family of Rhomboid intramembrane proteases activates all <i>Drosophila</i> membrane-tethered EGF ligands"; <u>The EMBO Journal</u> 21(16):4277-4286, 2002		
	AS	DATABASE; EMBL Accession Number BC014225; " <i>Homo sapiens</i> rhomboid family 1 ( <i>Drosophila</i> ), mRNA (cDNA clone MGC:220194 IMAGE:4650826), complete cds"; September 23, 2001		
	AT	DATABASE; PAT_PRT Accession Number AX658345; "Sequence 261 from Patent WO03000928"; March 21, 2003		
	AU	DATABASE; SWALL Accession Number Q9H6E1; "Hypothetical protein FLJ22357"; March 1, 2001		
	AV	DATABASE; SWALL Accession Number Z96CC6; "Hypothetical protein"; December 1, 2001		
	AW	DATABASE; SWALL Accession Number Q96S34; "Hypothetical protein"; December 1, 2001		
	AX	DATABASE; SWALL Accession Number Q8VIK0; "C16ORF8"; March 1, 2002		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.